Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Ardelyx, Inc., a biopharmaceutical company, announced that Mike Raab, CEO, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 1:10 p.m. ET. The live webcast can be accessed via the Investor section of the Ardelyx website, with replays available for 60 days post-event. Ardelyx focuses on innovative therapies for kidney and cardiovascular diseases, including tenapanor, currently under FDA review with a PDUFA date of April 29, 2021, and has established international partnerships for its development.

News Market Reaction – ARDX

+3.91%

+3.91% Session move

In the trading session that priced this news, ARDX gained 3.91%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FREMONT, Calif., Nov. 10, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. ET.

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the webcast will be available on the Ardelyx website for 60 days following the presentation.

About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA goal date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA^® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-virtual-london-healthcare-conference-301169441.html

SOURCE Ardelyx

FAQ

When will Ardelyx participate in the Jefferies Virtual London Healthcare Conference?

Ardelyx will participate on November 17, 2020, at 1:10 p.m. ET.

How can I access the webcast of Ardelyx's presentation?

The webcast can be accessed through the Investor section of Ardelyx's website.

What is the PDUFA date for Ardelyx's tenapanor NDA?

The PDUFA goal date for Ardelyx's tenapanor NDA is April 29, 2021.

What therapies is Ardelyx developing for kidney diseases?

Ardelyx is developing tenapanor for controlling serum phosphorus and RDX013 for treating hyperkalemia.

What countries have partnerships for the development of tenapanor?

Partnerships for tenapanor have been established in Japan, China, and Canada.